IcoSema for treating adults with type 2 diabetes

IcoSema is currently in phase 3 clinical development for type 2 diabetes. Type 2 diabetes is a lifelong condition that develops when the body becomes resistant to or does not produce enough insulin – a hormone produced in the pancreas that enables sugar to enter body cells. Signs and symptoms of type 2 diabetes often develop slowly. When signs and symptoms are present, they may include increased thirst, frequent urination, increased hunger, unintended weight loss etc. Current treatment options vary from oral tablet medications to injectables including Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which help the body create insulin, and insulin itself.